[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
5. Lo-Coco F, Fouad TM, Ramadan SM: Acute leukemia in women. Womens Health (Lond); 2010 Mar;6(2):239-49
MedlinePlus Health Information. consumer health - Women's Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute leukemia in women.
  • The treatment and survival outcome of acute leukemia in women is generally similar to that of men.
  • However, acute leukemia in women poses additional challenges in clinical practice.
  • In addition to important precautions during therapy, such as prevention of abnormal uterine bleeding in premenopausal women and therapy during pregnancy, women who are survivors of acute leukemia face unique and potentially long-term health-related problems.
  • In this review, we address the aforementioned issues, as well as the various health and psychosocial challenges faced by women who survive childhood leukemia during their path to adulthood.
  • Finally, we address the issue of therapy-related acute leukemia in the category of women who are survivors of breast and ovarian cancer.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Quality of Life. Survivors / statistics & numerical data. Women's Health

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20187729.001).
  • [ISSN] 1745-5065
  • [Journal-full-title] Women's health (London, England)
  • [ISO-abbreviation] Womens Health (Lond)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 130
  •  go-up   go-down


6. Razzouk BI, Rose SR, Hongeng S, Wallace D, Smeltzer MP, Zacher M, Pui CH, Hudson MM: Obesity in survivors of childhood acute lymphoblastic leukemia and lymphoma. J Clin Oncol; 2007 Apr 1;25(10):1183-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Obesity in survivors of childhood acute lymphoblastic leukemia and lymphoma.
  • PURPOSE: We evaluated the long-term effects of treatment on the body mass index (BMI) of children with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma who received one of three CNS-directed therapies: intrathecal methotrexate with intravenous high-dose methotrexate (1 g/m2), intrathecal methotrexate with 18 Gy cranial radiation, or intrathecal methotrexate with 24 Gy cranial radiation.
  • CONCLUSION: BMI weight category at diagnosis, rather than type of CNS treatment received, predicted adult weight in long-term survivors of childhood hematologic malignancies.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Cranial Irradiation / adverse effects. Methotrexate / adverse effects. Obesity / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


7. Irving J, Jesson J, Virgo P, Case M, Minto L, Eyre L, Noel N, Johansson U, Macey M, Knotts L, Helliwell M, Davies P, Whitby L, Barnett D, Hancock J, Goulden N, Lawson S, UKALL Flow MRD Group, UK MRD steering Group: Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting. Haematologica; 2009 Jun;94(6):870-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting.
  • Minimal residual disease detection, used for clinical management of children with acute lymphoblastic leukemia, can be performed by molecular analysis of antigen-receptor gene rearrangements or by flow cytometric analysis of aberrant immunophenotypes.
  • We report a four color, flow cytometric protocol established and validated by the UK acute lymphoblastic leukemia Flow minimal residual disease group.
  • The combined risk category concordance (minimal residual disease levels above or below 0.01%) was 86% (n=134).
  • [MeSH-major] Flow Cytometry / methods. Leukemia, B-Cell / diagnosis. Neoplasm, Residual / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Feb 1;95(3):790-4 [10648387.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2691-6 [11023499.001]
  • [Cites] Leukemia. 2000 Nov;14(11):1939-43 [11069029.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1253-8 [11830473.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1952-8 [11877265.001]
  • [Cites] Blood. 2002 Jul 1;100(1):52-8 [12070008.001]
  • [Cites] Leukemia. 2004 Mar;18(3):499-504 [14981525.001]
  • [Cites] Leukemia. 2004 May;18(5):934-8 [15029212.001]
  • [Cites] Acta Haematol. 2004;112(1-2):8-15 [15178999.001]
  • [Cites] Leukemia. 2004 Oct;18(10):1630-6 [15295608.001]
  • [Cites] J Biol Regul Homeost Agents. 2004 Apr-Jun;18(2):146-54 [15471219.001]
  • [Cites] Lancet. 1998 Feb 21;351(9102):550-4 [9492773.001]
  • [Cites] Br J Haematol. 1998 Jul;102(2):553-65 [9695973.001]
  • [Cites] N Engl J Med. 1998 Aug 27;339(9):591-8 [9718378.001]
  • [Cites] Blood. 1998 Sep 1;92(5):1838 [9716617.001]
  • [Cites] Blood. 1998 Dec 1;92(11):4072-9 [9834212.001]
  • [Cites] Lancet. 1998 Nov 28;352(9142):1731-8 [9848348.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3774-81 [9850021.001]
  • [Cites] Leukemia. 2005 Jan;19(1):49-56 [15538405.001]
  • [Cites] Am J Clin Pathol. 2004 Dec;122 Suppl:S47-57 [15690642.001]
  • [Cites] Br J Haematol. 2005 Mar;128(6):774-82 [15755280.001]
  • [Cites] Cytometry B Clin Cytom. 2005 Nov;68(1):18-24 [16184615.001]
  • [Cites] Haematologica. 2006 Aug;91(8):1109-12 [16885052.001]
  • [Cites] Leukemia. 2007 Apr;21(4):622-6 [17301806.001]
  • [Cites] Cytometry B Clin Cytom. 2008 Nov;74(6):331-40 [18548617.001]
  • [Cites] Blood. 2008 Nov 15;112(10):3982-8 [18780832.001]
  • [CommentIn] Haematologica. 2009 Jun;94(6):748-52 [19483150.001]
  • (PMID = 19377076.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD34; 0 / Receptors, Antigen, T-Cell; EC 3.4.24.11 / Neprilysin
  • [Other-IDs] NLM/ PMC2688581
  • [Investigator] Irving J; Jesson J; Virgo P; Case M; Minto L; Eyre L; Noel N; Johansson U; Macey M; Knotts L; Helliwell M; Davies P; Whitby L; Barnett D; Hancock J; Goulden N; Lawson S
  •  go-up   go-down


8. Kabuto M, Nitta H, Yamamoto S, Yamaguchi N, Akiba S, Honda Y, Hagihara J, Isaka K, Saito T, Ojima T, Nakamura Y, Mizoue T, Ito S, Eboshida A, Yamazaki S, Sokejima S, Kurokawa Y, Kubo O: Childhood leukemia and magnetic fields in Japan: a case-control study of childhood leukemia and residential power-frequency magnetic fields in Japan. Int J Cancer; 2006 Aug 1;119(3):643-50
MedlinePlus Health Information. consumer health - Electromagnetic Fields.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood leukemia and magnetic fields in Japan: a case-control study of childhood leukemia and residential power-frequency magnetic fields in Japan.
  • We analyzed 312 case children (0-15 years old) newly diagnosed with acute lymphoblastic leukemia (ALL) or acute myelocytic leukemia (AML) in 1999-2001 (2.3 years) and 603 controls matched for gender, age and residential area.
  • The odds ratios for children whose bedrooms had MF levels of 0.4 microT or higher compared with the reference category (MF levels below 0.1 microT) was 2.6 (95% CI=0.76-8.6) for AML+ALL and 4.7 (1.15-19.0) for ALL only.
  • Most of the leukemia cases in the highest exposure category had MF levels far above 0.4 microT.
  • Our results provided additional evidence that high MF exposure was associated with a higher risk of childhood leukemia, particularly of ALL.
  • [MeSH-major] Electromagnetic Fields / adverse effects. Leukemia, Myeloid / etiology. Leukemia, Radiation-Induced / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology
  • [MeSH-minor] Acute Disease. Case-Control Studies. Child. Child, Preschool. Environmental Exposure / adverse effects. Female. Geography. Housing / standards. Humans. Infant. Japan / epidemiology. Logistic Models. Male. Odds Ratio. Risk Factors. Seasons

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16496405.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


9. Glodkowska E, Bialas A, Jackowska T: [Comparison of the present and previously used protocol of risk stratification in children with acute lymphoblastic leukemia]. Med Wieku Rozwoj; 2007 Apr-Jun;11(2 Pt 1):153-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of the present and previously used protocol of risk stratification in children with acute lymphoblastic leukemia].
  • INTRODUCTION: Acute lymphoblastic leukaemia (ALL) is one of the most common cancers in children.
  • Part of the children was moved to the standard risk group (SR), part to high risk group (HR), and the rest remains in the intermediate risk category (IR).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / classification. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Risk Assessment / methods

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17625285.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; ALL-BFM-95 protocol; PVDA protocol
  •  go-up   go-down


10. Usvasalo A, Savola S, Räty R, Vettenranta K, Harila-Saari A, Koistinen P, Savolainen ER, Elonen E, Saarinen-Pihkala UM, Knuutila S: CDKN2A deletions in acute lymphoblastic leukemia of adolescents and young adults: an array CGH study. Leuk Res; 2008 Aug;32(8):1228-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CDKN2A deletions in acute lymphoblastic leukemia of adolescents and young adults: an array CGH study.
  • We were unable to demonstrate prognostic value of the deletion, however patients with deletion belonged more often (P=0.06) to unfavorable biological category.
  • [MeSH-major] Genes, p16. Oligonucleotide Array Sequence Analysis / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Sequence Deletion

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18328560.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


11. Liu KY, Chen YH, Liu DH, Xu LP, Huang XJ: A pilot study of low-dose recombinant interleukin-2 for acute lymphoblastic malignancy after unmanipulated allogeneic blood and marrow transplantation. Bone Marrow Transplant; 2008 Oct;42(8):535-9
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot study of low-dose recombinant interleukin-2 for acute lymphoblastic malignancy after unmanipulated allogeneic blood and marrow transplantation.
  • The objective of this study was to determine the efficacy and safety of low-dose recombinant interleukin-2(IL-2) administered to patients with acute lymphoblastic malignancy at high-risk of relapse after unmanipulated HLA-identical or HLA-haploidentical allogeneic hematopoietic stem cell transplantation (allo-HSCT).
  • We studied 19 patients with acute lymphoblastic malignancy who underwent IL-2 treatment for a high probability of disease recurrence after allo-HSCT between July 2004 and June 2006 at Peking University Institute of Hematology.
  • With a median follow-up of 6 months (range, 3-19 months) after the first IL-2 therapy, 14 of 15 evaluable patients in our cohort were disease-free (93.33%), whereas one patient in 'high risk' pretransplantation category relapsed.
  • In conclusion, low-dose IL-2 subcutaneous administration from 100 days for a prolonged period could be a safe and effective strategy to prevent relapse in acute lymphoblastic malignancy patients with high risk of recurrence after unmanipulated allo-HSCT.
  • [MeSH-major] Interleukin-2 / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / prevention & control

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18641681.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / IL2 protein, human; 0 / Interleukin-2
  •  go-up   go-down


12. Urs L, Stevens L, Kahwash SB: Leukemia presenting as solid tumors: report of four pediatric cases and review of the literature. Pediatr Dev Pathol; 2008 Sep-Oct;11(5):370-6
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukemia presenting as solid tumors: report of four pediatric cases and review of the literature.
  • Involvement of extramedullary tissue during the course of a leukemia is common and usually does not represent a major diagnostic challenge when the history is available and specimen triage is optimal.
  • In the lymphoid category, leukemia involvement of tissue is conventionally distinguished from lymphoma by establishing the presence of 20% or more blasts in the bone marrow.
  • A leukemia with an initial presentation outside the bone marrow mimicking a solid tumor is a rare but well-documented clinical encounter.
  • Systematic handling and proper triaging of biopsies are the keys to reducing diagnostic error and facilitating a timely diagnosis in this category.
  • [MeSH-major] Leukemia, Myeloid, Acute / pathology. Leukemia, Myelomonocytic, Juvenile / pathology. Neoplasms / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18179285.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 19
  •  go-up   go-down


13. Zalina AZ Jr, Suzana S, A Rahman AJ, Noor Aini MY: Assessing the nutritional status of children with leukemia from hospitals in kuala lumpur. Malays J Nutr; 2009 Mar;15(1):45-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing the nutritional status of children with leukemia from hospitals in kuala lumpur.
  • A cross-sectional study was carried out to evaluate the nutritional status of 51 subjects with leukemia aged 4 to 12 years from the Haematology and Oncology Paediatric Ward, Universiti Kebangsaan Malaysia Medical Centre (PPUKM) and the Paediatric Institute of Kuala Lumpur.
  • The subjects were diagnosed as acute lymphoblastic leukemia (ALL) (84.3%) followed by acute myelogenous leukemia (AML) (13.7%) and chronic myelogenous leukemia (CML) (2.0%) respectively.
  • Approximately 20.0% of the subjects were in the severe malnutrition category with respect to low serum albumin levels (<3.5g/dl).
  • While the results indicated no significant differences in the nutritional status of subjects with leukemia at different stages of treatment, it was observed that the prevalence of malnutrition was higher in children with newly diagnosed leukemia.
  • Thus, the nutritional status of children with leukemia should be monitored closely as there is a likelihood of deterioration owing to the disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22691804.001).
  • [ISSN] 1394-035X
  • [Journal-full-title] Malaysian journal of nutrition
  • [ISO-abbreviation] Malays J Nutr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Malaysia
  •  go-up   go-down


1
Advertisement
4. Ribeiro KB, Buffler PA, Metayer C: Socioeconomic status and childhood acute lymphocytic leukemia incidence in São Paulo, Brazil. Int J Cancer; 2008 Oct 15;123(8):1907-12
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Socioeconomic status and childhood acute lymphocytic leukemia incidence in São Paulo, Brazil.
  • Each child was assigned to an SES category based on the district of residence at diagnosis.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18688860.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


15. Gandemer V, Rio AG, de Tayrac M, Sibut V, Mottier S, Ly Sunnaram B, Henry C, Monnier A, Berthou C, Le Gall E, Le Treut A, Schmitt C, Le Gall JY, Mosser J, Galibert MD: Five distinct biological processes and 14 differentially expressed genes characterize TEL/AML1-positive leukemia. BMC Genomics; 2007;8:385
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Five distinct biological processes and 14 differentially expressed genes characterize TEL/AML1-positive leukemia.
  • BACKGROUND: The t(12;21)(p13;q22) translocation is found in 20 to 25% of cases of childhood B-lineage acute lymphoblastic leukemia (B-ALL).
  • This rearrangement results in the fusion of ETV6 (TEL) and RUNX1 (AML1) genes and defines a relatively uniform category, although only some patients suffer very late relapse.
  • RESULTS: We compared the leukemia cell gene expression profiles of 16 TEL/AML1-positive ALL patients to those of 44 TEL/AML1-negative patients, whose blast cells did not contain any additional recurrent translocation.
  • CONCLUSION: Gene expression analyses of leukemia cells from 60 children with TEL/AML1-positive and -negative B-lineage ALL led to the identification of five biological processes, associated with 14 validated genes characterizing and highlighting the biology of the TEL/AML1-positive ALL sub-group.
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / genetics. Gene Expression Profiling / methods. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Hematol. 2000 Oct;37(4):381-95 [11071360.001]
  • [Cites] Leuk Res. 2007 Sep;31(9):1317-9 [17113638.001]
  • [Cites] Blood. 2001 Aug 1;98(3):558-64 [11468150.001]
  • [Cites] Leuk Lymphoma. 2001 Jun;42(1-2):41-56 [11699220.001]
  • [Cites] Nat Genet. 2002 Jan;30(1):41-7 [11731795.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] Cancer Cell. 2002 Jun;1(5):417-20 [12124171.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3118-30 [12374679.001]
  • [Cites] Leuk Res. 2003 Feb;27(2):155-64 [12526921.001]
  • [Cites] Biotechniques. 2003 Feb;34(2):374-8 [12613259.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1679-82 [12886264.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2951-9 [12730115.001]
  • [Cites] Cancer Sci. 2003 Oct;94(10):841-6 [14556655.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2249-50 [14523475.001]
  • [Cites] Leuk Res. 2004 Jan;28(1):35-42 [14630078.001]
  • [Cites] Blood. 2004 Feb 1;103(3):1043-9 [14525776.001]
  • [Cites] BMC Bioinformatics. 2004 Feb 18;5:16 [14975175.001]
  • [Cites] BMC Genomics. 2004 Sep 23;5:71 [15387886.001]
  • [Cites] J Pediatr Hematol Oncol. 1998 May-Jun;20(3):190-5 [9628428.001]
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] Blood. 2005 Jan 15;105(2):821-6 [15388585.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):375-86 [15837626.001]
  • [Cites] Br J Haematol. 2005 Jul;130(1):26-35 [15982341.001]
  • [Cites] Leuk Res. 2005 Sep;29(9):1089-94 [16038737.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Oct 1;162(1):21-9 [16157196.001]
  • [Cites] Eur J Cancer. 2006 Mar;42(4):534-41 [16412629.001]
  • [Cites] Leukemia. 2006 Mar;20(3):410-6 [16424874.001]
  • [Cites] Blood. 2007 Feb 1;109(3):926-35 [17003380.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • (PMID = 17956600.001).
  • [ISSN] 1471-2164
  • [Journal-full-title] BMC genomics
  • [ISO-abbreviation] BMC Genomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein
  • [Other-IDs] NLM/ PMC2211320
  •  go-up   go-down


16. Khalade A, Jaakkola MS, Pukkala E, Jaakkola JJ: Exposure to benzene at work and the risk of leukemia: a systematic review and meta-analysis. Environ Health; 2010;9:31
Hazardous Substances Data Bank. BENZENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exposure to benzene at work and the risk of leukemia: a systematic review and meta-analysis.
  • BACKGROUND: A substantial number of epidemiologic studies have provided estimates of the relation between exposure to benzene at work and the risk of leukemia, but the results have been heterogeneous.
  • To bridge this gap in knowledge, we synthesized the existing epidemiologic evidence on the relation between occupational exposure to benzene and the risk of leukemia, including all types combined and the four main subgroups acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML).
  • The summary effect size for any leukemia from the fixed-effects model was 1.40 (95% CI, 1.23-1.57), but the study-specific estimates were strongly heterogeneous (I2 = 56.5%, Q stat = 34.47, p = 0.003).
  • In these studies the risk of leukemia increased with a dose-response pattern with a summary-effect estimate of 1.64 (95% CI, 1.13-2.39) for low (< 40 ppm-years), 1.90 (95% CI, 1.26-2.89) for medium (40-99.9 ppm-years), and 2.62 (95% CI, 1.57-4.39) for high exposure category (> 100 ppm-years).
  • The risk of AML also increased from low (1.94, 95% CI, 0.95-3.95), medium (2.32, 95% CI, 0.91-5.94) to high exposure category (3.20, 95% CI, 1.09-9.45), but the trend was not statistically significant.
  • CONCLUSIONS: Our study provides consistent evidence that exposure to benzene at work increases the risk of leukemia with a dose-response pattern.
  • [MeSH-major] Benzene / toxicity. Leukemia / chemically induced. Occupational Exposure / adverse effects
  • [MeSH-minor] Humans. Leukemia, Lymphocytic, Chronic, B-Cell / chemically induced. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / chemically induced. Leukemia, Myeloid, Acute / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / chemically induced. Risk Factors

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Occup Environ Med. 1996 Nov;53(11):773-81 [9038803.001]
  • [Cites] Environ Health Perspect. 1989 Jul;82:289-97 [2676500.001]
  • [Cites] Epidemiology. 1997 May;8(3):318-20 [9115030.001]
  • [Cites] Occup Environ Med. 1997 Mar;54(3):152-66 [9155776.001]
  • [Cites] J Natl Cancer Inst. 1997 Jul 16;89(14):1065-71 [9230889.001]
  • [Cites] Occup Environ Med. 1997 Sep;54(9):686-91 [9423584.001]
  • [Cites] Am J Ind Med. 1999 Mar;35(3):287-94 [9987562.001]
  • [Cites] Occup Environ Med. 2005 Apr;62(4):231-6 [15778255.001]
  • [Cites] Chem Biol Interact. 2005 May 30;153-154:9-21 [15935796.001]
  • [Cites] Chem Biol Interact. 2005 May 30;153-154:43-53 [15935799.001]
  • [Cites] Occup Med (Lond). 2007 May;57(3):177-85 [17244595.001]
  • [Cites] Cancer Causes Control. 2008 Feb;19(1):13-23 [17906934.001]
  • [Cites] Environ Health Perspect. 2008 Mar;116(3):370-4 [18335105.001]
  • [Cites] Am J Ind Med. 2008 Nov;51(11):803-11 [18651579.001]
  • [Cites] Am J Ind Med. 2002 Dec;42(6):474-80 [12439870.001]
  • [Cites] Scand J Work Environ Health. 2003 Feb;29(1):51-9 [12630436.001]
  • [Cites] Occup Environ Med. 2003 Sep;60(9):676-9 [12937190.001]
  • [Cites] Epidemiology. 2003 Sep;14(5):569-77 [14501272.001]
  • [Cites] Occup Environ Med. 2004 Mar;61(3):270-4 [14985523.001]
  • [Cites] Am J Ind Med. 1997 Mar;31(3):287-95 [9055951.001]
  • (PMID = 20584305.001).
  • [ISSN] 1476-069X
  • [Journal-full-title] Environmental health : a global access science source
  • [ISO-abbreviation] Environ Health
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] J64922108F / Benzene
  • [Number-of-references] 23
  • [Other-IDs] NLM/ PMC2903550
  •  go-up   go-down


17. Schüz J, Forman MR: Birthweight by gestational age and childhood cancer. Cancer Causes Control; 2007 Aug;18(6):655-63
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The odds ratio for acute lymphoblastic leukemia (ALL) was 1.41 (95% confidence interval 1.08-1.84) in the high-birthweight category (>4 kg) and was 1.45 (1.07-1.97) in the large-for-gestational age (LGA) category compared to the normal birthweight (2.5-4 kg) and the appropriate-for-gestational age (AGA) categories, respectively.
  • [MeSH-minor] Adolescent. Case-Control Studies. Child. Child, Preschool. Confidence Intervals. Female. Germany / epidemiology. Humans. Infant. Infant, Newborn. Logistic Models. Male. Odds Ratio. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Registries. Risk Factors

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Birth Weight.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17503007.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


18. Castro EC, Blazquez C, Boyd J, Correa H, de Chadarevian JP, Felgar RE, Graf N, Levy N, Lowe EJ, Manning JT Jr, Proytcheva MA, Senger C, Shayan K, Sterba J, Werner A, Surti U, Jaffe R: Clinicopathologic features of histiocytic lesions following ALL, with a review of the literature. Pediatr Dev Pathol; 2010 May-Jun;13(3):225-37

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe the clinicopathologic features of 15 patients who had histiocytic lesions that followed acute lymphoblastic leukemia (ALL).
  • Most were atypical for the category by histology, phenotype, or abnormally high turnover rate.
  • For those evaluated, the molecular signature of the prior leukemia was present in the histiocytic lesion.
  • In 3 of 15 patients, the leukemia and histiocytic lesion shared immunoglobulin H or monoclonal TCR gene rearrangements and, in 4 of 15 patients, clonal identity was documented by fluorescence in situ hybridization.
  • The post-ALL lesions are more aggressive than their native counterparts, but despite the demonstration of the presence of the leukemia signature in 7 of 15 patients, the prognosis is generally favorable, except for patients with histiocytic sarcoma.
  • [MeSH-major] Histiocytes / pathology. Histiocytosis / pathology. Neoplasms, Multiple Primary / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19642834.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  • [Number-of-references] 43
  •  go-up   go-down


19. Hołowiecki J: Indications for hematopoietic stem cell transplantation. Pol Arch Med Wewn; 2008 Nov;118(11):658-63
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • According to the EBMT recommendations, the following categories of indications have been used: "standard procedure" category--S, "clinical option"--CO, indication of "developmental" character--D and "generally not recommended"--NR.
  • Generally, the most-common indications for auto-transplant treatment are myeloma, malignant lymphoma and acute myeloblastic leukemia while the main indication for bone marrow allotransplantation is acute myeloblastic leukemia (33% of all allotransplantations), lymphoblastic leukemia, dysmyelopoietic syndrome, chronic myeloblastic leukemia refractory to tyrosine kinase inhibitors, then lymphoid malignancies and non-malignant disorders (bone marrow aplasia, severe immunodeficiencies, paroxysmal nocturnal hemoglobinuria, etc.).
  • [MeSH-major] Bone Marrow Transplantation / statistics & numerical data. Hematopoietic Stem Cell Transplantation / statistics & numerical data. Leukemia / therapy. Lymphoma / therapy


20. Hovén E, Anclair M, Samuelsson U, Kogner P, Boman KK: The influence of pediatric cancer diagnosis and illness complication factors on parental distress. J Pediatr Hematol Oncol; 2008 Nov;30(11):807-14
MedlinePlus Health Information. consumer health - Stress.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We used a model in which "complicated childhood cancers" were grouped into 1 category, after identifying a set of potentially influential illness complication variables.
  • This category included central nervous system tumors, acute myeloid leukemia, and bone tumors.
  • Parental distress in that category (n=144) was compared with distress after acute lymphoblastic leukemia (n=177) in the child.
  • RESULTS: Parents in the complicated cancer category showed significantly heightened disease-related fear, anxiety, depression, loss of control, late effects-related uncertainty, and poorer self-esteem compared with parents of children with acute lymphoblastic leukemia.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18989157.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


21. Nething J, Ringwald-Smith K, Williams R, Hancock ML, Hale GA: Establishing the use of body mass index as an indicator of nutrition risk in children with cancer. JPEN J Parenter Enteral Nutr; 2007 Jan-Feb;31(1):53-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: This study was conducted by a retrospective chart review of 1839 newly diagnosed acute lymphoblastic leukemia patients at St. Jude Children's Research Hospital.
  • Those falling below the 10(th) percentile on any one category of height for age (HFA), weight for age (WFA), or weight for height (WFH) were classified with regard to nutrition risk and compared with those identified as at risk by BMI for age (BFA).
  • [MeSH-major] Body Mass Index. Leukemia, Lymphoid / complications. Nutrition Assessment. Nutrition Disorders / diagnosis. Nutritional Status

  • MedlinePlus Health Information. consumer health - Acute Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Nutrition.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17202441.001).
  • [ISSN] 0148-6071
  • [Journal-full-title] JPEN. Journal of parenteral and enteral nutrition
  • [ISO-abbreviation] JPEN J Parenter Enteral Nutr
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R25 CA023944
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Miano M, Labopin M, Hartmann O, Angelucci E, Cornish J, Gluckman E, Locatelli F, Fischer A, Egeler RM, Or R, Peters C, Ortega J, Veys P, Bordigoni P, Iori AP, Niethammer D, Rocha V, Dini G, Paediatric Diseases Working Party of the European Group for Blood and Marrow Transplantation: Haematopoietic stem cell transplantation trends in children over the last three decades: a survey by the paediatric diseases working party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant; 2007 Jan;39(2):89-99
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data were taken from the EBMT registry and were compared according to period and centre category (paediatric or combined).
  • The number of allogeneic HSCTs (allo-HSCTs) for acute lymphoblastic leukaemia, acute myeloblastic leukaemia and chronic myeloid leukaemia remained stable, whereas it increased for myelodysplastic syndromes and lymphomas, and decreased significantly for non-malignant diseases (P<0.0001).
  • The number of autologus HSCTs (auto-HSCTs) for acute leukaemia decreased significantly, whereas it increased for solid tumours (P<0.0001).
  • [MeSH-minor] Blood Transfusion / statistics & numerical data. Bone Marrow Transplantation / statistics & numerical data. Child. Data Collection. Europe. Humans. Leukemia / therapy. Registries. Transplantation, Autologous. Transplantation, Homologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17213848.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


23. Karanes C, Nelson GO, Chitphakdithai P, Agura E, Ballen KK, Bolan CD, Porter DL, Uberti JP, King RJ, Confer DL: Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program. Biol Blood Marrow Transplant; 2008 Sep;14(9 Suppl):8-15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chronic myelogenous leukemia (CML) was previously the most common diagnosis for unrelated donor transplantation, but it now comprises less than 10% of transplants for adult recipients.
  • Transplants for acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), and myelodysplastic syndromes (MDS) all outnumber CML.
  • Correspondingly, survival within each disease category has improved.

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18721775.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


24. Radeva JI, VanScoyoc E, Smith FO, Curtis LH, Breitfeld PP: National estimates of the use of hematopoietic stem-cell transplantation in children with cancer in the United States. Bone Marrow Transplant; 2005 Sep;36(5):397-404
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We identified cancer encounters for children aged 18 years and younger from 1997 to 2001 in US nonfederal, acute care hospitals.
  • We compared patient, hospital, and resource use characteristics and in-patient mortality associated with HSCT and non-HSCT encounters, estimated the number of HSCT encounters by stem-cell source and cancer type, and examined resource use and mortality in each category.
  • Of note, 17% of HSCT encounters were for patients with acute lymphoblastic leukemia without remission or sarcoma, conditions for which there is little evidence of benefit from HSCT in children.

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15995713.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


25. Segal BH, Freifeld AG: Antibacterial prophylaxis in patients with neutropenia. J Natl Compr Canc Netw; 2007 Feb;5(2):235-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among patients with neutropenia at lower risk for infectious complications (a category that includes most patients with solid tumor malignancies), the main benefit of antibacterial prophylaxis relates to a reduction in fever rather than documented infections.
  • Trimethoprim-sulfamethoxazole should be used in patients at risk for Pneumocystis jiroveci (formerly P carinii), such as childhood acute lymphoblastic leukemia.

  • MedlinePlus Health Information. consumer health - Bacterial Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17335692.001).
  • [ISSN] 1540-1405
  • [Journal-full-title] Journal of the National Comprehensive Cancer Network : JNCCN
  • [ISO-abbreviation] J Natl Compr Canc Netw
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / Antineoplastic Agents
  • [Number-of-references] 56
  •  go-up   go-down


26. Urayama KY, Ma X, Buffler PA: Exposure to infections through day-care attendance and risk of childhood leukaemia. Radiat Prot Dosimetry; 2008;132(2):259-66
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exposure to infections through day-care attendance and risk of childhood leukaemia.
  • There is growing evidence supporting a role for infections in the aetiology of childhood leukaemia.
  • Hypotheses proposed by both Greaves and Kinlen describe childhood leukaemia to be a rare response to one or more common infections acquired through personal contacts.
  • Within the Northern California Childhood Leukaemia Study, the role of social contact has been assessed and a unique 'child-hours' summary measure incorporating information on the number of months attending a day-care, mean hours per week at this day-care and the number of children in the day-care setting was constructed.
  • In this review, the previously reported day-care results have been described, showing that in non-Hispanic White children, children in the highest category of total child-hours of exposure had a reduced risk of acute lymphoblastic leukaemia (ALL), particularly common B-cell precursor ALL (c-ALL), compared with children without such exposures, with evidence of a dose-response effect.

  • MedlinePlus Health Information. consumer health - Child Care.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMJ. 2005 Jun 4;330(7503):1294 [15849205.001]
  • [Cites] Br J Cancer. 1999 Jul;80(9):1483-9 [10424755.001]
  • [Cites] Haematologica. 2006 Feb;91(2):240-3 [16461310.001]
  • [Cites] Nat Rev Cancer. 2006 Mar;6(3):193-203 [16467884.001]
  • [Cites] Environ Health Perspect. 2007 Jan;115(1):146-50 [17366835.001]
  • [Cites] Br J Cancer. 2007 Nov 5;97(9):1315-21 [17923868.001]
  • [Cites] Leukemia. 2008 Jan;22(1):189-93 [17690702.001]
  • [Cites] Br J Cancer. 2000 Jan;82(1):234-40 [10638995.001]
  • [Cites] Br J Cancer. 2000 Dec;83(11):1559-64 [11076669.001]
  • [Cites] Am J Epidemiol. 2000 Dec 15;152(12):1136-44 [11130619.001]
  • [Cites] Br J Cancer. 2002 Apr 8;86(7):1064-9 [11953850.001]
  • [Cites] Br J Cancer. 2002 May 6;86(9):1419-24 [11986774.001]
  • [Cites] Paediatr Perinat Epidemiol. 2002 Apr;16(2):154-65 [12060313.001]
  • [Cites] Am J Epidemiol. 2003 Jan 15;157(2):176-82 [12522025.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):139-45 [14710221.001]
  • [Cites] Am J Epidemiol. 2004 May 15;159(10):915-21 [15128601.001]
  • [Cites] Br J Haematol. 2004 Nov;127(3):243-63 [15491284.001]
  • [Cites] Leukemia. 1988 Feb;2(2):120-5 [3278171.001]
  • [Cites] Lancet. 1988 Dec 10;2(8624):1323-7 [2904050.001]
  • [Cites] Am J Epidemiol. 1990 Jan;131(1):1-5 [2403464.001]
  • [Cites] Pediatrics. 1991 Jan;87(1):62-9 [1984620.001]
  • [Cites] BMJ. 1993 Sep 25;307(6907):774 [8219951.001]
  • [Cites] Pediatrics. 1994 Dec;94(6 Pt 2):987-90 [7971086.001]
  • [Cites] J Epidemiol Community Health. 1994 Dec;48(6):601-2 [7830017.001]
  • [Cites] Epidemiol Rev. 1996;18(1):10-28 [8877328.001]
  • [Cites] Br J Cancer. 1997;76(9):1241-7 [9365177.001]
  • [Cites] Br J Cancer. 1999 May;80(3-4):585-90 [10408870.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1928-34 [16103439.001]
  • (PMID = 18940822.001).
  • [ISSN] 0144-8420
  • [Journal-full-title] Radiation protection dosimetry
  • [ISO-abbreviation] Radiat Prot Dosimetry
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / PS42 ES04705; United States / NIEHS NIH HHS / ES / R01 ES09137
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2879097
  •  go-up   go-down


27. Yang MH, Yen CC, Chiang SC, Bai LY, Lee KD, Hsiao LT, Chao TC, Wang WS, Liu JH, Chiou TJ, Chen PM: Prognostic significance of clonal diversity of immunoglobulin gene rearrangements in patients with diffuse large B-cell lymphoma. Oncol Rep; 2005 Mar;13(3):503-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clonal diversity of the immunoglobulin (Ig) gene rearrangement represents the oligoclonality of B-cell neoplasm, and has been shown to be a marker for poor prognosis in acute lymphoblastic leukemia.
  • Survival analysis showed that clonal diversity is an independent prognostic factor in DLBCL (p=0.05, Cox's proportional hazard method), and stratified analyses found the most significant subgroup is the high-intermediate risk category (p=0.01, log-rank test).
  • It is also a factor of poor prognosis in DLBCL, especially for high-intermediate risk category.

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15706425.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


28. Wood L, Haveman J, Juritz J, Waldman H, Hale G, Jacobs P: Immunohematopoietic stem cell transplantation in Cape Town: a ten-year outcome analysis in adults. Hematol Oncol Stem Cell Ther; 2009;2(2):320-32
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this report, we summarize the demography and outcome by disease category, gender, and type of procedure in patients older than 18 years of age who were seen from April 1995 to December 2002.
  • At 96 months of follow-up, a stable plateau was reached for each disease category.
  • Median survival was 3.3 years (n=6, 14.6%) for acute lymphoblastic anemia, 3.1 years (n=44, 18%) for acute myeloid leukemia, 2.8 years (n=47, 19%) for chronic granulocytic leukemia, 2.8 years (n=71, 29%) for lymphoma, 1.5 years (n=23, 9%) for myeloma, 1.43 years (n=10, 4%) for aplasia, and 1.4 years (n=38, 15%) for a miscellaneous group comprising less than 10 examples each.

  • Genetic Alliance. consumer health - TEN.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20118055.001).
  • [ISSN] 1658-3876
  • [Journal-full-title] Hematology/oncology and stem cell therapy
  • [ISO-abbreviation] Hematol Oncol Stem Cell Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


29. Rosenman MB, Vik T, Hui SL, Breitfeld PP: Hospital resource utilization in childhood cancer. J Pediatr Hematol Oncol; 2005 Jun;27(6):295-300
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patients were categorized into four diagnostic groups: lymphoid malignancies (acute lymphoblastic leukemia and lymphoma), myeloid leukemias (acute myeloid leukemia and chronic myeloid leukemia), central nervous system tumors, and solid tumors.
  • Hospital charges and length of stay for patients in each diagnostic category were described.
  • The distribution of 165 diagnoses was as follows: 65 (39%) with lymphoid malignancy, 13 (8%) with myeloid leukemia, 36 (22%) with central nervous system tumors, and 51 (31%) with solid tumors.
  • Half of all hospital charges accrued to only 12.7% of patients; these patients were more likely to have a diagnosis of myeloid leukemia, to have undergone stem cell transplantation, and to have used the PICU.
  • PICU utilization was predicted by tumor type (myeloid leukemia and central nervous system tumors were positive predictors of PICU utilization; lymphoid malignancy and solid tumors were negative predictors), stem cell transplantation, and death within 3 years of diagnosis.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15956880.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / NLM NIH HHS / LM / 1T15 LM 07117
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down






Advertisement